Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 137

Sort by

Sort Order Select

Journal Articles

Investigating the Novel Combination of the Innate Cell Engager (ICE®) Acimtamig with Off-the-Shelf Allogeneic Natural Killer Cells AlloNK® in Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Initial Results of the Phase 2 Luminice-203 Study

Joseph Maakaron, Dipenkumar Modi, Matthew Mei, Tatyana Feldman, Gunjan L. Shah, Amitkumar N. Mehta, Craig S. Sauter, Rashmi Khanal, Stefan K. Barta, Michael Emig, Lydia Wunderle, Andre Overesch, Alexandra Vasile, Jennifer Rubel, Thorsten Graef, Heather Raymon, Alison Moskowitz

Blood (2024) 144 (Supplement 1): 3052.

https://doi.org/10.1182/blood-2024-193896

Published: 2024

Journal Articles

Loncastuximab Tesirine in Combination with Venetoclax Is Safe and Shows Efficacy in Patients with Relapsed/Refractory Non Hodgkin Lymphoma

Paolo F. Caimi, Allison M. Winter, Robert M. Dean, Taylor R. Brooks, Deepa Jagadeesh, Craig S. Sauter, Brian T. Hill

Blood (2024) 144 (Supplement 1): 4499.

https://doi.org/10.1182/blood-2024-202154

Published: 2024

Journal Articles

Outcomes of Waldenström Macroglobulinemia Patients Requiring Therapeutic Plasma Exchange. Higher Rates of Progression and Resistance of Initial Systemic Therapy

Jessica Leng, Jack Khouri, Allison M. Winter, Deepa Jagadeesh, Robert M. Dean, Taylor R. Brooks, Louis Williams, Faiz Anwer, Craig S. Sauter, Brian T. Hill, Paolo F. Caimi

Blood (2024) 144 (Supplement 1): 6342.

https://doi.org/10.1182/blood-2024-206344

Published: 2024

Journal Articles

Treatment Patterns and Outcomes Following Progression of Disease Post-CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter Analysis

Blood (2024) 144 (Supplement 1): 238.

https://doi.org/10.1182/blood-2024-192995

Published: 2024

Journal Articles

Two Decade Single Institution Experience Highlights Rare Survivors with Relapsed or Refractory Burkitt Lymphoma

Blood (2024) 144 (Supplement 1): 6520.

https://doi.org/10.1182/blood-2024-210617

Published: 2024

Journal Articles

Effect of Prior Daratumumab Treatment on Hematopoietic Progenitor Cell Mobilization in Newly Diagnosed Multiple Myeloma

Daniel Cancilla, Joseph Farinella, Amanda Inman, Hong Li, Craig S. Sauter, Faiz Anwer, Claudio Brunstein, Shahzad Raza, Louis Williams, Jack Khouri

Blood (2024) 144 (Supplement 1): 7260.

https://doi.org/10.1182/blood-2024-209082

Published: 2024

Journal Articles

Comparison of Adverse Effects of Two Mobilization Regimens for Autologous Hematopoietic Cell Transplant in Multiple Myeloma

Daniel Cancilla, Daniel P. Nurse, Christina Ferraro, Craig S. Sauter, Jack Khouri

Blood (2024) 144 (Supplement 1): 7259.

https://doi.org/10.1182/blood-2024-209019

Published: 2024

Journal Articles

Assessment of Secondary Malignancies after Allogeneic Hematopoietic Cell Transplant When Comparing Treatment with and without Post-Transplant Cyclophosphamide

Daniel P. Nurse, Wei Wei, Amanda Burns, Joseph Farinella, Deepa Jagadeesh, Robert M. Dean, Rabi Hanna, Seth J Rotz, Aaron T. Gerds, Claudio Brunstein, Matt Kalaycio, Craig S. Sauter, Betty K. Hamilton, Ronald Sobecks

Blood (2024) 144 (Supplement 1): 7383.

https://doi.org/10.1182/blood-2024-202626

Published: 2024

Journal Articles

Factors Associated with Platelet Engraftment Following Allogeneic Hematopoietic Cell Transplantation

Andrew D. Trunk, Hong Li, Matt Kalaycio, Ronald Sobecks, Claudio Brunstein, Craig S. Sauter, Betty K. Hamilton

Blood (2024) 144 (Supplement 1): 3488.

https://doi.org/10.1182/blood-2024-204051

Published: 2024

Journal Articles

Prevalence and Outcomes of Opportunistic Infections in Steroid Refractory Graft Versus Host Disease Patients Treated with Ruxolitinib, Ibrutinib, and Belumosudil

Victoria Stepanyants, Hong Li, Danielle Cenin, Jessi Edwards, Claudio Brunstein, Matt Kalaycio, Ronald Sobecks, Craig S. Sauter, Betty K. Hamilton

Blood (2024) 144 (Supplement 1): 2145.

https://doi.org/10.1182/blood-2024-199329

Published: 2024

Journal Articles

Chimeric Antigen Receptor (CAR) T Cell Infusion for Large B Cell Lymphoma in Complete Remission: A Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis

Trent Wang, Kwang Wooahn, Manmeet Kaur, Mazyar Shadman, Alex F. Herrera, Craig S Sauter, Mehdi Hamadani, Antonio M. Jimenez Jimenez

Blood (2023) 142 (Supplement 1): 615.

https://doi.org/10.1182/blood-2023-179223

Published: 2023

Journal Articles

Pilot Study of Longitudinal Geriatric Assessment and Neurocognitive Evaluation in CAR T-Cell Therapy for Older Patients with Relapsed Refractory, Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 7406.

https://doi.org/10.1182/blood-2023-190497

Published: 2023

Journal Articles

Day 100 Risk Assessment Tool Predicts 1 Year Survival in Allogeneic Hematopoietic Cell Transplant Patients

Joseph Farinella, Lauren M Granat, Hong Li, Sharon M Caroniti, Pranay S. Hegde, Matt Kalaycio, Ronald Sobecks, Claudio Brunstein, Craig S Sauter, Betty K. Hamilton

Blood (2023) 142 (Supplement 1): 3725.

https://doi.org/10.1182/blood-2023-189629

Published: 2023

Journal Articles

Autologous Transplant (auto-HCT) Is Associated with Improved Clinical Outcomes Compared to CAR-T Therapy in Patients (pts) with Large B-Cell Lymphoma (LBCL) Achieving a Complete Remission

Mazyar Shadman, Kwang Wooahn, Manmeet Kaur, Mohamed A. Kharfan-Dabaja, Alex F. Herrera, Craig S Sauter, Mehdi Hamadani

Blood (2023) 142 (Supplement 1): 781.

https://doi.org/10.1182/blood-2023-173536

Published: 2023

Journal Articles

Long Term Follow-up after Treatment with Allogeneic Off-the-Shelf CAR T Cell Therapy for Relapsed or Refractory B-Cell Malignancies

Sanam Shahid, Georgia C Flynn, Audrey Mauguen, Jennifer Bieler, Susan E Prockop, Andromachi Scaradavou, Jaap Jan Boelens, Craig S Sauter, Miguel-Angel Perales, Sergio A. Giralt, Xiuyan Wang, Isabelle Riviere, Michel Sadelain, Renier Brentjens, Nancy A Kernan, Richard J O'Reilly, Kevin J Curran

Blood (2023) 142 (Supplement 1): 3476.

https://doi.org/10.1182/blood-2023-180753

Published: 2023

Journal Articles

Impact of Prior Lines of Therapy before Autologous Hematopoietic Cell Transplant on Survival in Standard Risk Multiple Myeloma

Hussein Awada, Ali Hajj Ali, Danai Dima, Craig S Sauter, Louis Williams, Jack Khouri, Shahzad Raza, Sandra Mazzoni, Jason Valent, Christy J. Samaras, Faiz Anwer

Blood (2023) 142 (Supplement 1): 7069.

https://doi.org/10.1182/blood-2023-189995

Published: 2023

Journal Articles

Resource Utilization Analysis of Two Algorithms for Hematopoietic Progenitor Cell Mobilization in Multiple Myeloma

Daniel Cancilla, Daniel (Paul) Nurse, Wei Wei, Christina Ferraro, Brian Matia, Julie Coffman, Craig S Sauter, Betty K. Hamilton, Jack Khouri

Blood (2023) 142 (Supplement 1): 6942.

https://doi.org/10.1182/blood-2023-178831

Published: 2023

Journal Articles

A Phase 1 Study of NKX101, a Chimeric Antigen Receptor Natural Killer (CAR-NK) Cell Therapy, with Fludarabine and Cytarabine in Patients with Acute Myeloid Leukemia

Craig S Sauter, Gautam Borthakur, Luke Mountjoy, Marcello Rotta, Hongtao Liu, Hemant S. Murthy, Ming Lin, James Trager, Cornell Chang, Nishi Kothari, David Shook, Carlos Bachier

Blood (2023) 142 (Supplement 1): 2097.

https://doi.org/10.1182/blood-2023-173582

Published: 2023

Journal Articles

Influence of Pre-Transplant Estimated Glomerular Filtration Rate (eGFR) on Outcomes after Allogeneic Hematopoietic Cell Transplantation

Ronald Sobecks, Hong Li, Danielle Cenin, Seema Patel, Jesse Edwards, Stephanie Farlow, Amelia Bragg, Rabi Hanna, Seth J Rotz, Deepa Jagadeesh, Aaron T. Gerds, Robert M. Dean, Brad Pohlman, Betty K. Hamilton, Claudio Brunstein, Matt Kalaycio, Craig S Sauter

Blood (2023) 142 (Supplement 1): 3621.

https://doi.org/10.1182/blood-2023-187071

Published: 2023

Journal Articles

A Phase II Trial of Prophylactic Anakinra to Prevent Neurotoxicity in Patients Receiving Anti-CD19 CAR T-Cell Therapy for Relapsed or Refractory Lymphoma: Final Results from Cohort 2

Blood (2023) 142 (Supplement 1): 357.

https://doi.org/10.1182/blood-2023-174728

Published: 2023

NARROW

Investigating the Novel Combination of the Innate Cell Engager (ICE®) Acimtamig with Off-the-Shelf Allogeneic Natural Killer Cells AlloNK® in Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Initial Results of the Phase 2 Luminice-203 Study

Loncastuximab Tesirine in Combination with Venetoclax Is Safe and Shows Efficacy in Patients with Relapsed/Refractory Non Hodgkin Lymphoma

Outcomes of Waldenström Macroglobulinemia Patients Requiring Therapeutic Plasma Exchange. Higher Rates of Progression and Resistance of Initial Systemic Therapy

Treatment Patterns and Outcomes Following Progression of Disease Post-CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter Analysis

Two Decade Single Institution Experience Highlights Rare Survivors with Relapsed or Refractory Burkitt Lymphoma

Effect of Prior Daratumumab Treatment on Hematopoietic Progenitor Cell Mobilization in Newly Diagnosed Multiple Myeloma

Comparison of Adverse Effects of Two Mobilization Regimens for Autologous Hematopoietic Cell Transplant in Multiple Myeloma

Assessment of Secondary Malignancies after Allogeneic Hematopoietic Cell Transplant When Comparing Treatment with and without Post-Transplant Cyclophosphamide

Factors Associated with Platelet Engraftment Following Allogeneic Hematopoietic Cell Transplantation

Prevalence and Outcomes of Opportunistic Infections in Steroid Refractory Graft Versus Host Disease Patients Treated with Ruxolitinib, Ibrutinib, and Belumosudil

Chimeric Antigen Receptor (CAR) T Cell Infusion for Large B Cell Lymphoma in Complete Remission: A Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis

Pilot Study of Longitudinal Geriatric Assessment and Neurocognitive Evaluation in CAR T-Cell Therapy for Older Patients with Relapsed Refractory, Large B-Cell Lymphoma

Day 100 Risk Assessment Tool Predicts 1 Year Survival in Allogeneic Hematopoietic Cell Transplant Patients

Autologous Transplant (auto-HCT) Is Associated with Improved Clinical Outcomes Compared to CAR-T Therapy in Patients (pts) with Large B-Cell Lymphoma (LBCL) Achieving a Complete Remission

Long Term Follow-up after Treatment with Allogeneic Off-the-Shelf CAR T Cell Therapy for Relapsed or Refractory B-Cell Malignancies

Impact of Prior Lines of Therapy before Autologous Hematopoietic Cell Transplant on Survival in Standard Risk Multiple Myeloma

Resource Utilization Analysis of Two Algorithms for Hematopoietic Progenitor Cell Mobilization in Multiple Myeloma

A Phase 1 Study of NKX101, a Chimeric Antigen Receptor Natural Killer (CAR-NK) Cell Therapy, with Fludarabine and Cytarabine in Patients with Acute Myeloid Leukemia

Influence of Pre-Transplant Estimated Glomerular Filtration Rate (eGFR) on Outcomes after Allogeneic Hematopoietic Cell Transplantation

A Phase II Trial of Prophylactic Anakinra to Prevent Neurotoxicity in Patients Receiving Anti-CD19 CAR T-Cell Therapy for Relapsed or Refractory Lymphoma: Final Results from Cohort 2

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only